Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, today ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology SymposiumFebruary 28, 2019 5:01 PM Pre-Open Stock Movers 02/26: (HTZ) (EVER) (MNK) Higher; (AMR) (CAT) (TSLA) Lower (more...)February 26, 2019 9:23 AM Heat Biologics (HTBX) Gains on HS-110 Phase 2 Trial AbstractFebruary 26, 2019 7:11 AM